New Research Reveals Phelan-McDermid Syndrome Prevalence Is Significantly Higher Than Previously Estimated
New research conducted by scientists at the Seaver Autism Center for Research and Treatment at Mount Sinai suggests that Phelan-McDermid syndrome (PMS) is significantly more prevalent than earlier clinical estimates had indicated. The findings, published in the journal Autism Research, represent a major shift in how clinicians and geneticists understand the reach of this rare genetic disorder. By synthesizing data from nearly 180,000 individuals with autism, the study estimates that PMS affects approximately 1 in 7,300 people, a figure that suggests upwards of 45,000 individuals in the United States may be living with the condition, many of whom remain undiagnosed.
Understanding Phelan-McDermid Syndrome: A Genetic Foundation
Phelan-McDermid syndrome, historically referred to as 22q13.3 deletion syndrome, is a complex genetic disorder primarily caused by a deletion or mutation involving the SHANK3 gene located on chromosome 22. The SHANK3 gene is critical for the development and function of synapses, the connections between neurons that facilitate communication throughout the brain. When this gene is compromised, the resulting physiological disruption leads to a wide spectrum of medical, intellectual, and behavioral challenges.
The phenotypic expression of the syndrome is notoriously broad, ranging from global developmental delays and moderate-to-severe intellectual disability to absent or delayed speech and neonatal hypotonia. Furthermore, most individuals diagnosed with PMS meet the diagnostic criteria for autism spectrum disorder (ASD). Current clinical consensus suggests that mutations affecting SHANK3 alone account for as much as one percent of all autism spectrum disorder cases, underscoring its role as a significant, albeit often overlooked, contributor to neurodevelopmental diversity.
Chronology of Discovery and Diagnostic Evolution
The history of PMS identification is relatively recent. First described in the late 1980s by Dr. Katy Phelan and Dr. Heather McDermid, the condition was initially identified through cytogenetic analysis—the study of chromosomes under a microscope. As genomic technology advanced throughout the early 2000s, the use of chromosomal microarray analysis (CMA) became the gold standard, allowing for more precise identification of microdeletions that were previously invisible to standard karyotyping.
Despite these technological leaps, the "diagnostic odyssey" for many families remains arduous. The current study highlights that the discrepancy between historical prevalence estimates and the new 1-in-7,300 figure is largely a product of systemic barriers in the healthcare landscape. For years, clinicians often limited genetic testing to cases presenting with extreme physical dysmorphology or severe cognitive impairment. Consequently, individuals with milder presentations or those who lacked access to specialized pediatric neurology centers were often excluded from genetic screening, leading to a persistent undercount in clinical registries.
Data Synthesis: A Comprehensive Meta-Analysis
To arrive at their updated prevalence estimates, the team at Mount Sinai orchestrated a collaborative data-sharing effort that spanned ten major genetic testing laboratories and research cohorts. This included data from GeneDx, Labcorp, Ambry Genetics, the SPARK research study, and the Autism Sequencing Consortium, alongside contributions from prominent children’s hospitals.
By aggregating information from 180,000 individuals who had already undergone some form of genetic testing, the researchers were able to perform a more robust statistical modeling exercise than any previous attempt. The methodology involved a multi-step adjustment process: researchers accounted for cases that remained undiagnosed despite testing, the inherent sensitivity limits of various genetic panels, and the subset of the PMS population that does not present with overt autism symptoms. This comprehensive approach yielded a prevalence estimate of 13.7 cases per 100,000 people.
Expert Perspectives and Barriers to Care
Tess Levy, MSc, Assistant Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai and the study’s first author, emphasized that the gap between known and estimated cases is a public health concern. "The large gap between known and estimated cases is likely due in large part to the fact that many individuals with developmental disabilities and autism are never offered genetic testing," Levy noted.
Beyond the lack of universal screening protocols, Levy pointed to secondary challenges: families frequently navigate significant insurance barriers that classify genetic testing as "not medically necessary" or "experimental," or they are provided with limited screening panels that fail to adequately interrogate the SHANK3 gene. These systemic hurdles ensure that thousands of patients remain without a molecular diagnosis, effectively barring them from targeted support and research participation.
Joseph D. Buxbaum, PhD, Director of the Seaver Autism Center and senior author of the paper, argues that the shift toward universal genetic testing for children with autism is no longer just a research priority—it is a clinical necessity. "We recommend that every child with autism undergo genetic testing, because knowledge is power," Buxbaum stated. "These genetic findings allow researchers to design more targeted clinical trials for potential therapies. I truly believe that within the next five years, we’ll see successful examples of new treatments coming from these genetic discoveries."
The Ethical Imperative for Diagnosis
The urgency of this research is amplified by the current pipeline of pharmaceutical development. Support for the study was provided by CureSHANK and Neuren Pharmaceuticals, both of whom have a vested interest in the clinical advancement of therapies for PMS. The collaboration highlights a growing consensus that identifying patients is an ethical mandate, not merely an academic exercise.
Dr. Rachel Groth, Head of External Innovation and Patient Advocacy at Neuren Pharmaceuticals, articulated this stance clearly: "Neuren Pharmaceuticals initiated this landmark PMS prevalence study in collaboration with the Seaver Autism Center at Mount Sinai and CureSHANK because, with new treatments moving closer to reality, identifying these individuals has become an ethical imperative. Patients cannot benefit from these advances if they never receive a diagnosis."
For many families, a genetic diagnosis provides clarity that can transform the trajectory of care. It shifts the focus from managing behavioral symptoms in isolation to addressing the underlying biological drivers of the disorder. It also connects families with specialized medical care, research studies, and patient advocacy networks, such as CureSHANK, which provide essential emotional and logistical support.
Implications for Precision Medicine
The findings arrive at a pivotal moment in the history of precision medicine. As clinical trials for PMS move into more advanced phases—targeting the specific neurobiological pathways disrupted by the SHANK3 mutation—the ability to identify the patient population becomes the primary bottleneck.
Geraldine Bliss, Board Chair of CureSHANK, echoed the optimism of the research team. "This study confirms what many families, clinicians, and advocates have suspected for years," Bliss said. "There are likely tens of thousands of individuals with Phelan-McDermid syndrome who have never received a genetic diagnosis. At a time when multiple therapeutics are advancing into clinical trials, finding these individuals has never been more important."
This research serves as a catalyst for the broader "Start Genetic" campaign, a global initiative encouraging healthcare providers to prioritize genetic inquiry at the point of care for any child showing signs of developmental delay or autism. By moving from a "symptom-first" approach to a "genetic-first" approach, the medical community hopes to collapse the distance between discovery and diagnosis.
Future Outlook
As genomic sequencing costs continue to decline and the availability of broad-spectrum testing panels increases, the findings from the Seaver Autism Center are likely to be validated by future, even larger-scale screenings. The implication is clear: Phelan-McDermid syndrome is not merely a rare genetic curiosity, but a widespread neurodevelopmental condition that requires integrated, systemic attention.
For the families affected, the promise of this research lies in the potential for disease-modifying treatments that could, for the first time, address the biological basis of the syndrome. However, for those breakthroughs to have impact, the healthcare system must evolve. Universal access to genetic testing for neurodevelopmental disorders remains the essential bridge between the current status quo of uncertainty and a future defined by precision medicine and improved quality of life for the tens of thousands of individuals currently living in the shadow of an undiagnosed condition.
